Teva Pharmaceuticals and APP Pharmaceuticals have announced the commercial launch of a generic form of Gemzar® in the USA.
The two companies are now marketing gemcitabine hydrochloride (HCI) for injection in 200 mg and 1 g single dose vials.
Gemzar is a chemotherpay drug used to treat non small cell lung cancer,
pancreatic cancer, metastatic breast cancer, and ovarian cancer.
Annual sales of Eli Lilly and Company’s Gemzar® were approximately $785 million in the USA in 2010, based on IMS sales data.
Under an agreement signed by the two companies, APP will manufacture gemcitabine HCI for injection and will receive a license from Teva to market the product within Teva’s 180-day exclusivity.
In return, Teva will receive a royalty during the manufacturing term.
Tim Crew, Senior Vice President, Commercial Operations – Generics at Teva, commented: “We are pleased to enter into this agreement with APP, which allows us to accelerate the availability of this important generic product.
“This agreement is another example of Teva’s commitment to providing consumers with access to high-quality, affordable medicines.”